Epidemiological trends of HIV/HCV coinfection in Spain, 2015-2019.


Journal

HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392

Informations de publication

Date de publication:
08 2022
Historique:
revised: 17 12 2021
received: 01 10 2021
accepted: 23 12 2021
pubmed: 18 1 2022
medline: 14 7 2022
entrez: 17 1 2022
Statut: ppublish

Résumé

We assessed the prevalence of anti-hepatitis C virus (HCV) antibodies and active HCV infection (HCV-RNA-positive) in people living with HIV (PLWH) in Spain in 2019 and compared the results with those of four similar studies performed during 2015-2018. The study was performed in 41 centres. Sample size was estimated for an accuracy of 1%. Patients were selected by random sampling with proportional allocation. The reference population comprised 41 973 PLWH, and the sample size was 1325. HCV serostatus was known in 1316 PLWH (99.3%), of whom 376 (28.6%) were HCV antibody (Ab)-positive (78.7% were prior injection drug users); 29 were HCV-RNA-positive (2.2%). Of the 29 HCV-RNA-positive PLWH, infection was chronic in 24, it was acute/recent in one, and it was of unknown duration in four. Cirrhosis was present in 71 (5.4%) PLWH overall, three (10.3%) HCV-RNA-positive patients and 68 (23.4%) of those who cleared HCV after anti-HCV therapy (p = 0.04). The prevalence of anti-HCV antibodies decreased steadily from 37.7% in 2015 to 28.6% in 2019 (p < 0.001); the prevalence of active HCV infection decreased from 22.1% in 2015 to 2.2% in 2019 (p < 0.001). Uptake of anti-HCV treatment increased from 53.9% in 2015 to 95.0% in 2019 (p < 0.001). In Spain, the prevalence of active HCV infection among PLWH at the end of 2019 was 2.2%, i.e. 90.0% lower than in 2015. Increased exposure to DAAs was probably the main reason for this sharp reduction. Despite the high coverage of treatment with direct-acting antiviral agents, HCV-related cirrhosis remains significant in this population.

Identifiants

pubmed: 35037379
doi: 10.1111/hiv.13229
pmc: PMC9543728
doi:

Substances chimiques

Antiviral Agents 0
RNA 63231-63-0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

705-716

Investigateurs

C Fanciulli (C)
L Pérez-Latorre (L)
T Aldámiz (T)
C Díez (C)
F Tejerina (F)
S Carretero (S)
I Gutiérrez (I)
M Ramírez (M)
B Padilla (B)
J C López (JC)
J Berenguer (J)
M J Núñez (MJ)
F Arnalich (F)
J R Arribas (JR)
J I Bernardino (JI)
C Busca (C)
A Delgado (A)
V Hontañón (V)
M L Martín-Carbonero (ML)
R Micán (R)
R Montejano (R)
M L Montes (ML)
V Moreno (V)
I Pérez-Valero (I)
C Navarro (C)
E Valencia (E)
J González-García (J)
A Rivero-Juárez (A)
T Brieva (T)
I Machuca (I)
A Camacho (A)
A Rivero-Román (A)
I Jarrín (I)
M J Vivancos (MJ)
S Moreno (S)
A Moreno (A)
J L Casado (JL)
M J Pérez-Elías (MJ)
C Quereda (C)
A Torrella (A)
B Planas (B)
J Navarro (J)
M Rodrigo (M)
V Estrada (V)
J Vergas (J)
M J Téllez (MJ)
J Muñoz (J)
M Gutiérrez (M)
G Mateo (G)
J M Guardiola (JM)
M Ibarguren (M)
M P Carmona (MP)
F Rodríguez-Arrondo (F)
M A Goenaga (MA)
H Azkune (H)
M A Von Wichmann (MA)
J A Iribarren (JA)
J Carmena (J)
A Artero (A)
E Prado-González (E)
G Piera-Rojo (G)
A Ocampo (A)
C Miralles (C)
M Crespo (M)
Morano L (M)
J Ruiz (J)
E Nuño (E)
R Palacios (R)
J Santos (J)
M Márquez (M)
J Sanz (J)
I Santos (I)
J Moreno (J)
P Arazo (P)
M Montero (M)
M Tasias (M)
S Cuellar (S)
E Calabuig (E)
M Blanes (M)
J Fernández (J)
J López-Aldeguer (J)
M Salavert (M)
A Hernando (A)
L Domínguez (L)
O Bisbal (O)
M De Lagarde (M)
M Matarranz (M)
R Rubio (R)
F Pulido (F)
C García (C)
C Armiñanzas (C)
S Echevarría (S)
M Gutiérrez-Cuadra (M)
C Fariñas (C)
L Giner (L)
S Reus (S)
E Merino (E)
V Boix (V)
D Torrús (D)
I Portilla (I)
M Pampliega (M)
M Díez (M)
I Egea (I)
J Portilla (J)
O L Ferrero (OL)
S Ibarra (S)
I López (I)
M de la Peña (M)
Z Zubero (Z)
J Baraia (J)
J Muñoz (J)
J de Miguel (J)
A Arranz (A)
E Casas (E)
J Sanz (J)
A Ferrer (A)
M J Galindo (MJ)
L García (L)
L Pérez (L)
J A Oteo (JA)
M Velasco (M)
L Moreno (L)
R Hervás (R)
J E Losa (JE)
D Vinuesa (D)
L Muñoz (L)
J Hernández-Quero (J)
S Veloso (S)
J Peraire (J)
C Viladés (C)
M Vargas (M)
A Castellano (A)
F Vidal (F)
R Silvariño (R)
A J Orti (AJ)
E Chamarro (E)
C Escrig (C)
P Geijo (P)
A Chocarro (A)
C Rodríguez (C)
T Puerta (T)
M Raposo (M)
M Vera (M)
J Del Romero (J)
J Bisbe (J)
C Cifuentes (C)
R Teira (R)
J Vilaró (J)
A Vegas (A)
A Cano (A)
A Alcaráz (A)
A Muñoz (A)
E Bernal (E)
M Campoamor (M)
M J Tuya (MJ)
B de la Fuente (B)
A Gimeno (A)
C Montero (C)
S Arponen (S)
L Force (L)
P Barrufet (P)
G Gaspar (G)
G Alonso (G)
C Toledo (C)
A I Peláez (AI)
G Lara (G)
I Fernández (I)
M C Esteban (MC)

Informations de copyright

© 2022 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.

Références

AIDS. 2012 Nov 13;26(17):2241-6
pubmed: 22781223
J Hepatol. 2020 May;72(5):855-864
pubmed: 31862485
Lancet HIV. 2021 Feb;8(2):e96-e105
pubmed: 33357835
Liver Int. 2019 Mar;39(3):416-426
pubmed: 30472772
Open Forum Infect Dis. 2016 Mar 11;3(2):ofw059
pubmed: 27186584
Clin Infect Dis. 2009 May 15;48(10):1467-70
pubmed: 19368502
Hepatology. 2009 Aug;50(2):407-13
pubmed: 19575364
J Viral Hepat. 2018 Jun;25(6):680-698
pubmed: 29345844
Semin Liver Dis. 2012 May;32(2):130-7
pubmed: 22760652
Clin Infect Dis. 2001 Aug 15;33(4):562-9
pubmed: 11462196
Hepatology. 1999 Oct;30(4):1054-8
pubmed: 10498659
AIDS. 2019 Mar 15;33(4):685-689
pubmed: 30829744
Enferm Infecc Microbiol Clin. 2005 Jun-Jul;23(6):340-8
pubmed: 15970166
HIV Med. 2019 Apr;20(4):264-273
pubmed: 30734998
Euro Surveill. 2019 Jul;24(30):
pubmed: 31362808
Clin Infect Dis. 2012 Sep;55(5):728-36
pubmed: 22610932
Clin Infect Dis. 2000 Apr;30 Suppl 1:S77-84
pubmed: 10770916
Clin Infect Dis. 2019 Nov 27;69(12):2127-2135
pubmed: 30810158
HIV Med. 2022 Aug;23(7):705-716
pubmed: 35037379
N Engl J Med. 2014 May 22;370(21):2043-7
pubmed: 24795199
Hepatology. 2018 Jul;68(1):32-47
pubmed: 29377274
Open Forum Infect Dis. 2018 Jan 12;5(1):ofx258
pubmed: 29354658
Clin Infect Dis. 2014 Mar;58(5):719-27
pubmed: 24285848
Clin Infect Dis. 2020 Sep 12;71(6):1502-1510
pubmed: 31585005

Auteurs

Chiara Fanciulli (C)

Infectious Diseases and Clinical Microbiology, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain.
Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.

Juan Berenguer (J)

Infectious Diseases and Clinical Microbiology, Hospital General Universitario Gregorio Marañón (IiSGM), Madrid, Spain.
Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.

Carmen Busca (C)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
HIV Unit, Internal Medicine, Hospital Universitario La Paz (IdiPAZ), Madrid, Spain.

María J Vivancos (MJ)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
Infectious Diseases, Hospital Ramón y Cajal (Irycis), Madrid, Spain.

María J Téllez (MJ)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
Infectious Diseases, Hospital Clínico San Carlos, Madrid, Spain.

Lourdes Domínguez (L)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
HIV Unit, Internal Medicine, Hospital Universitario 12 de Octubre, Madrid, Spain.

Pere Domingo (P)

Infectious Diseases, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.

Jordi Navarro (J)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
Infectious Diseases, Hospital Universitari Vall d´Hebrón, Barcelona, Spain.

Jesús Santos (J)

Infectious Diseases, Hospital Clínico Universitario Virgen de la Victoria, Málaga, Spain.

José A Iribarren (JA)

Infectious Diseases, Hospital Donostia, San Sebastián, Spain.

Luis Morano (L)

Infectious Diseases, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain.

Arturo Artero (A)

Internal Medicine and Infectious Diseases, Hospital Universitario Doctor Peset, Valencia, Spain.

Javier Moreno (J)

Infectious Diseases, Hospital Universitario Miguel Servet, Zaragoza, Spain.

Antonio Rivero-Román (A)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
CIBERINFEC, Madrid, Spain.

Ignacio Santos (I)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
Infectious Diseases, Hospital Universitario de la Princesa, Madrid, Spain.

Livia Giner (L)

Infectious Diseases, Hospital General Universitario de Alicante, Alicante, Spain.

Carlos Armiñanzas (C)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
Infectious Diseases, Hospital Universitario Marqués de Valdecilla, Santander, Spain.

Marta Montero (M)

Infectious Diseases, Hospital Universitario y Politécnico La Fe, Valencia, Spain.

Christian Manzardo (C)

Infectious Diseases, Hospital Arnau de Vilanova, Lleida, Spain.
Infectious Diseases, Hospital Santa María, Lleida, Spain.

Carmen Cifuentes (C)

Infectious Diseases, Hospital Son Llàtzer, Palma de Mallorca, Mallorca, Spain.

Coral García (C)

Infectious Diseases, Hospital Universitario Virgen de las Nieves, Granada, Spain.

María J Galindo (MJ)

Internal Medicine and Infectious Diseases, Hospital Clínico de Valencia, Valencia, Spain.

Oscar L Ferrero (OL)

Infectious Diseases, Hospital Universitario de Basurto, Bilbao, Spain.

José Sanz (J)

Infectious Diseases, Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain.

Belén de la Fuente (B)

Infectious Diseases, Hospital Universitario de Cabueñes, Gijón, Spain.

Carmen Rodríguez (C)

Centro Sanitario Sandoval, Madrid, Spain.

Gabriel Gaspar (G)

Internal Medicine and Infectious Diseases, Hospital Universitario de Getafe, Getafe, Spain.

Laura Pérez (L)

Infectious Diseases, Hospital San Pedro, Logroño, Spain.

Juan E Losa (JE)

Infectious Diseases, Fundación Hospital Alcorcón, Alcorcón, Spain.

Luis Force (L)

Internal Medicine and Infectious Diseases, Hospital de Mataró, Mataró, Spain.

Sergio Veloso (S)

Infectious Diseases, Hospital Universitario Joan XXIII, Tarragona, Spain.

Elisa Martínez-Alfaro (E)

Infectious Diseases, Complejo Hospitalario Universitario de Albacete, Albacete, Spain.

Inmaculada Jarrín (I)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain.

Marta De Miguel (M)

Fundación SEIMC/GeSIDA, Madrid, Spain.

Juan González Garcia (J)

Unit of Infectious Diseases, Hospital Universitario Reina Sofia. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC), Universidad de Córdoba (UCO), Cordoba, Spain.
HIV Unit, Internal Medicine, Hospital Universitario La Paz (IdiPAZ), Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH